Expression of angiogenic basic fibroblast growth factor, platelet derived growth factor, thrombospondin-1 and their receptors at the porcine maternal-fetal interface.
BACKGROUND
Commercial swine breeds in North America undergo two waves of spontaneous fetal loss; one during peri-attachment and another during mid-gestation. Although an exact mechanism for this loss is not known, deficits in vasculature at the attachment sites appear to be a major cause. We hypothesized that a balance between pro-angiogenic and anti-angiogenic factors is needed at the maternal-fetal interface for successful conceptus development. Six selected members of the pro-angiogenic fibroblast growth factor (FGF) and platelet derived growth factor (PDGF) families and anti-angiogenic factor thrombospondin-1 (TSP-1) and its receptor CD36 were quantified and localized at the porcine maternal-fetal interface at early and midgestation time points.


METHODS
Mesometrial endometrium was collected from non-pregnant gilts (n = 8). Endometrial and chorioallantoic membrane samples were collected from healthy and arresting conceptus attachment sites at gestation day (gd) 20 (n = 8) and gd 50 (n = 8). At gd20 arresting conceptus attachment sites were distinguished by decreased vasculature of the placental membranes and decreased conceptus size. At gd50 arresting conceptuses attachment sites were identified by smaller conceptus length and weight measurements. Quantitative real time PCR was used to determine relative transcript levels of genes of interest, and cellular localization was determined by immunohistochemistry in paraffin embedded endometrial sections.


RESULTS
At gd20, endometrial samples from arresting conceptuses had elevated transcripts for bFGF, and PDGF-bb than healthy sites (p < 0.05). At gd50, bFGF, FGFR2, and CD36 were more abundant at arresting than at healthy conceptus attachment sites (p < 0.05). Chorioallantoic membrane from arresting conceptus attachment sites at gd20 had elevated transcripts for bFGF, FGFR1, FGFR2 and CD36 compared with healthy sites (p < 0.05). FGFR2 transcripts were more abundant in chorioallantoic membrane from arresting conceptuses at gd 50 (p < 0.05). Immunohistochemical localization of selected pro- and anti-angiogenic factors and receptors revealed their abundance in the luminal epithelium, uterine glands and perivascular areas of endometrium at gd20 and gd50.


CONCLUSIONS
We provide comprehensive analysis of pro and anti-angiogenic factors at the porcine maternal fetal interface during early and mid-pregnancy. At mRNA levels, the majority of pro-angiogenic factors investigated were elevated at the sites of fetal arrest. These observations contrast with our previous findings of decreased Vascular Endothelial Growth Factor (VEGF) family members at arresting sites, and suggest that the bFGF family functions as a compensatory survival mechanism when major angiogenic proteins are decreasing at the sites of fetal arrest.
Department of Biomedical Science, University of Guelph, Guelph, ON N1G 2W1, Canada. tayadec@queensu.ca
Andrew K
AK
Edwards
Marianne J
MJ
van den Heuvel
Jocelyn M
JM
Wessels
Jonathan
J
Lamarre
B Anne
BA
Croy
Chandrakant
C
Tayade
D000818:Animals; D000077214:Becaplermin; D018955:CD36 Antigens / Q000096:biosynthesis*; D049033:Chorioallantoic Membrane / Q000378:metabolism*; D004717:Endometrium / Q000378:metabolism; D005260:Female; D016222:Fibroblast Growth Factor 2 / Q000096:biosynthesis*; D005865:Gestational Age; D018919:Neovascularization, Physiologic; D010982:Platelet-Derived Growth Factor / Q000096:biosynthesis* / Q000502:physiology; D011247:Pregnancy; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger / Q000378:metabolism; D051496:Receptor, Fibroblast Growth Factor, Type 1 / Q000096:biosynthesis*; D051497:Receptor, Fibroblast Growth Factor, Type 2 / Q000096:biosynthesis*; D020796:Receptor, Platelet-Derived Growth Factor alpha / Q000096:biosynthesis; D020797:Receptor, Platelet-Derived Growth Factor beta / Q000096:biosynthesis; D034421:Sus scrofa; D019700:Thrombospondin 1 / Q000096:biosynthesis*
D018955:CD36 Antigens; D010982:Platelet-Derived Growth Factor; D020574:Proto-Oncogene Proteins c-sis; D012333:RNA, Messenger; D019700:Thrombospondin 1; D016222:Fibroblast Growth Factor 2; D000077214:Becaplermin; D051496:Receptor, Fibroblast Growth Factor, Type 1; D051497:Receptor, Fibroblast Growth Factor, Type 2; D020796:Receptor, Platelet-Derived Growth Factor alpha; D020797:Receptor, Platelet-Derived Growth Factor beta
Growth Factors. 1990;3(4):299-307
2257150
J Biol Chem. 1989 May 25;264(15):8771-8
2542288
Biol Reprod. 1998 Sep;59(3):491-6
9716545
Cytogenet Genome Res. 2003;102(1-4):179-83
14970699
J Exp Med. 2006 Nov 27;203(12):2613-25
17101731
J Immunol. 2006 Jan 1;176(1):148-56
16365405
Mol Reprod Dev. 1990 Oct;27(2):93-101
1979007
Microsc Res Tech. 1997 Jul 1-15;38(1-2):165-75
9260847
Immunol Cell Biol. 2010 Jan;88(1):63-71
19755977
Hum Reprod. 1993 Aug;8(8):1173-8
7691867
Biol Reprod. 1997 Jun;56(6):1527-36
9166706
J Biol Chem. 1989 May 25;264(15):8905-12
2542295
Eur J Cardiothorac Surg. 2008 Apr;33(4):645-50; discussion 251-2
18201892
J Steroid Biochem Mol Biol. 2004 Mar;88(3):295-304
15120423
J Leukoc Biol. 2007 Oct;82(4):877-86
17634279
Cell. 1985 May;41(1):301-12
2986848
J Cell Physiol. 2007 Mar;210(3):807-18
17154366
Biol Reprod. 2010 Aug 1;83(2):277-85
20393170
Nat Rev Immunol. 2006 Aug;6(8):584-94
16868549
Development. 1999 Jun;126(14):3047-55
10375497
J Reprod Dev. 2005 Aug;51(4):509-19
15976484
Cytokine Growth Factor Rev. 2005 Apr;16(2):159-78
15863032
J Anim Sci. 1999 Jul;77(7):1654-8
10438009
Science. 1997 Jul 11;277(5323):242-5
9211853
Microvasc Res. 2007 Sep-Nov;74(2-3):90-9
17559888
Am J Reprod Immunol. 2009 Mar;61(3):253-60
19239428
Growth Factors. 1994;11(3):175-86
7734143
Mol Biol Cell. 2002 Jun;13(6):1893-905
12058057
Dev Biol. 1999 Aug 1;212(1):124-36
10419690
Fertil Steril. 2005 Apr;83(4):1056-9
15820829
Cleve Clin J Med. 2009 Apr;76 Suppl 2:S27-30
19376978
J Mol Endocrinol. 1998 Dec;21(3):355-62
9845676